<p><strong>Pediatric use</strong>: The safety and efficacy of alectinib in children and adolescents (&lt;18 years) have not been studied.<br />
<br />
<strong>Geriatric use</strong>: No dose adjustment of alectinib is required in patients&ge;65 years of age.<br />
<br />
<strong>Renal impairment</strong>: No dose adjustment is required in patients with mild or moderate renal impairment. alectinib has not been studied in patients with severe renal impairment, however,since alectinib elimination via the kidney is negligible, no dose adjustment is required inpatients with severe renal impairment<br />
<br />
<strong>Hepatic impairment</strong>: No dose adjustment is required in patients with underlying mild or moderate hepatic impairment. Patients with underlying severe hepatic impairment should receive a dose of 450 mg given orally twice daily (total daily dose of 900 mg)</p>